In the past year, Biocon received marketing approvals in the European Union for both its biosimilar pegfilgrastim (sold as Fulphila) and its biosimilar trastuzumab (sold as Ogivri), which were co-developed in a partnership with Mylan.
Last week, Biocon released its third quarter earnings for fiscal year (FY) 2019 on an earnings call with investors. Included within the earnings report were updates on Biocon’s biosimilar pipeline.
“Our biosimilars strategy is beginning to pay off with the launch of our biosimilars in the [United States] and [European Union], and we are greatly encouraged by the recent regulatory approvals of our key biosimilars in advanced markets like [the European Union], Australia, and Canada,” said Kiran Mazumdar-Shaw, chairperson and managing director of Biocon. “We are committed to [playing] a significant role in enhancing access to our high quality, affordable biologics for patients across the world.”
In the past year, Biocon received marketing approvals in the European Union for both its biosimilar pegfilgrastim (sold as Fulphila) and its biosimilar trastuzumab (sold as Ogivri), which were co-developed in a partnership with Mylan. Both Ogivri and Fulphila are approved in the United States, though only Fulphila has thus far reached the US market.
Additionally, the third quarter for Biocon also saw the launch of 2 of its co-developed biosimilar products in the European Union: insulin glargine, Semglee, and biosimilar adalimumab, Hulio.
Biocon’s biologics arm alone brought in nearly $6,317,879 in Q3. This figure is more than double that of Q3 FY18, equal to a growth of 136% year over year, according to Biocon.
Last quarter was notable for Biocon’s company as a whole, and it boasted that “We have delivered the highest ever revenue and profit growth in absolute terms in Q3FY19, driven by strong business performance. Our biologics segment more than doubled in revenue and recorded an [earnings before interest and taxes, EBIT margin] of 30% driven by increased penetration of our pegfilgrastim in US small molecules, branded formulations, and research services also registered a robust growth this quarter,” said Mazumdar-Shaw.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.